OPDP accuses Acorda of improperly marketing MS drug

08/12/2013 | PharmaLive.com

The FDA's Office of Prescription Drug Promotion issued a warning letter to Acorda Therapeutics, accusing it of omitting information on risks, adverse events and contraindications in a newspaper ad for the company's Ampyra multiple sclerosis drug. Acorda was warned last year that a video for the same drug overstated efficacy and minimized risk information.

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN